Abstract
Recently several reports have demonstrated that innate immune response and inflammation have an important role in major neurodegenerative diseases. The activation of the NF-κB family of transcription factors is a key step in the regulation of pro inflammatory cytokine expression. Microglia and other cell types in the brain can be activated in response to endogenous danger molecules as well as aggregated proteins and brain injury. During the past couple of years several studies reported the role of cystatins in neuroinflammation and neurodegeneration. In the present review, I will summarize and analyze recent findings regarding the role of cystatins in inflammation and NF-κB activation. Type I cystatin stefin B (cystatin B) is an endogenous cysteine cathepsin inhibitor localized in the cytosol, mitochondria and nucleus. Mutations in the gene of stefin B are associated with the neurodegenerative disease known as Unverricht-Lundborg disease and microglial activation plays an important role in the pathogenesis of the disease. Stefin B deficient mice have increased caspase-11 expression and secreted higher amounts of pro-inflammatory cytokines. The increased caspase-11 gene expression, was a consequence of increased NF-κB activation.
Introduction
The innate immune response represents not only the first line of defense against invading microorganisms, but also responds to endogenous stress and has a crucial role in the pathology of neurodegenerative diseases in the central nervous system (CNS). It is elicited through the detection of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns DAMPS (Akira et al., 2006; Medzhitov, 2007). In the CNS, pattern-recognition receptors (PRRs) are primarily expressed by microglia and astrocytes. DAMPs are endogenous molecules, released by dying or damaged cells after cellular stress and can be recognized by PRRs such as membrane-bound toll-like receptors (TLRs) or cytosolic nucleotide-binding domain and leucine-rich repeat-containing (NLR), the RIG-I-like receptor (RLR), the AIM2-like receptor (ALR; Medzhitov, 2007; Moresco et al., 2011; Franchi et al., 2012). Triggering of PRRs by PAMPs or DAMPs results in signaling pathways that promote gene transcription by nuclear factor-κB (NF-κB) as well as interferon regulatory factors (IRFs) and leads to production of interferons and pro-inflammatory cytokines (Akira et al., 2006; Kawai and Akira, 2009). TLR4 and the extracellular adaptor protein MD-2 form a lipopolysacharide (LPS) receptor complex. Upon LPS binding and receptor homodimerization, the signal transducing adapter proteins become associated with the receptor and trigger the signaling pathway resulting in the activation of the nuclear NF-κB (Visintin et al., 2003; Medzhitov, 2007). With the exception of TLR3, TLRs and the IL-1R family use the adaptor MyD88 for signal transduction, which recruits the kinases}IRAK1 and IRAK4 as well as TRAF6 through its death domain (Muzio et al., 1997; Wesche et al., 1997; Kobayashi et al., 2002). The result of these sequential steps is the activation of inhibitors of NF-κB kinase (IKK) complex and the transcription factor nuclear factor kappa B (NF-κB). Viral PAMPs, like nucleic acids are recognized by endosomal TLRs −3, −7, −8 and −9, as well as by RLRs. Triggering endosomal TLRs by viral PAMPs leads to the activation of NF-κB and IRFs, which cooperatively mediate the production of IFN-α/β (Apostolou and Thanos, 2008). In the CNS, pattern-recognition receptors are primarily expressed by microglia, macrophages and astrocytes.
A crucial component of the innate immune response is the inflammasome, a NLR-based multiprotein complex responsible for the activation of caspase-1 (Martinon and Tschopp, 2007; Latz et al., 2013; Lamkanfi and Dixit, 2014). Members of the NLR family (NLR proteins –NLRP) and the adaptor ASC form multiprotein complexes which are required for the activation of the pro-inflammatory caspase-1 and subsequent processing of pro-interleukin (IL)-1β and pro-IL-18 into the mature forms that are released from the cell (Martinon and Tschopp, 2007; Takeuchi and Akira, 2010). The inflammasome activation should be tightly regulated in order to protect the host and limit the excessive inflammation. Recently, several excellent reviews described mechanism of inflammasome activation (Lamkanfi and Dixit, 2014; Guo et al., 2015). Particullary the activation of NLRP3 inflamamsome is well characterized (Martinon and Tschopp, 2007; Jabaut et al., 2013; Latz et al., 2013). The nucleotide binding and oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, is composed of NLRP3, the adaptor molecule apoptosis-associated speck-like protein which contain a caspase recruitment domain (ASC) and the cysteine protease caspase-1. The first, priming step is provided by TLR signaling that up-regulates NLPR3 and pro-IL-1β gene expression. This process is tightly controlled by signals culminating in the activation of NF-κB (Bauernfeind et al., 2009).
Recently not only canonical NLRP3 inflammasome activation (LPS and ATP), but also non-canonical inflammasome activation was reported (Kayagaki et al., 2011; Rathinam et al., 2012; Broz and Monack, 2013). Canonical inflammasomes activation results in procaspase-1 cleavage and activation, whereas the activation of a noncanonical inflammasome results in activation of procaspase-11 (Lamkanfi and Dixit, 2014). The canonical and noncanonical inflammasomes regulate release of IL-1α and IL-1β (Kayagaki et al., 2011). Both proinflamatory caspases-1 and -11 could induce pyroptosis, however only caspase-1 processes proforms of cytokines IL-1β and IL-18 into active forms which are secreted (Kayagaki et al., 2011). Recently two independent reports demonstrated that gasdermin D, a substate for caspase-11, was essential for caspase-11-dependent pyroptosis and interleukin-1β maturation (Kayagaki et al., 2015; Shi et al., 2015). Caspase-11 responds to cytoplasmic LPS independent of Toll-like receptor 4 (Hagar et al., 2013; Kayagaki et al., 2013). The mouse caspase-11 has high similarities to caspase-1 and is orthologous to human caspases-4 and -5 (Wang et al., 1996; Kajiwara et al., 2014). Interestingly, caspase-11-deficient mice, but not caspase-1-deficient mice are partially protected from septic death (Wang et al., 1998; Kayagaki et al., 2011).
In neurons NLRP1 and Aim2 inflammasomes were described (de Rivero Vaccari et al., 2009; Adamczak et al., 2014) and in microglia microglia NLRP3 (Halle et al., 2008), NLRP2 inflammasome was reported in human astrocytes (Minkiewicz et al., 2013). Recent study by Adamczak et al. (2014) reported that activation of the Aim2 inflammasome in neurons by cerebrospinal fluid from traumatic brain injury patients resulted in neuronal pyroptosis. Recently, several reviews described the role of innate immune response and inflammasome activation in neurodegenerative diseases (Heneka et al., 2014, 2015; Freeman and Ting, 2015). The CNS is particularly sensitive to IL-1β and IL-18 signaling because several cell types in the CNS express receptors for these cytokines (Allan et al., 2005; Alboni et al., 2010). Recently, several reviews described the role of innate immune response and inflammasome activation in neurodegenerative diseases (Heneka et al., 2014, 2015; Freeman and Ting, 2015).
Microglia and Astrocytes—Immune Cells in the Brain
In CNS, the blood-brain barrier (BBB) limits entry of peripherally derived innate and adaptive immune cells and their associated inflammatory molecule and plasma proteins (Banerjee and Bhat, 2007). Moreover, the CNS environment is anti-inflammatory, featuring high local concentrations of inflammation-suppressive cytokines such as TGF-β and IL-10 (Zocchia et al., 1997). Microglia are CNS-resident myeloid cells of embryonic hemeatopoietic origin and represent a major cellular component of the innate immune system in CNS (Aguzzi et al., 2013). Similar to tissue macrophages, microglia survey the brain for pathogens and support CNS homeostasis and plasticity; by guarding and remodeling synapses (Wake et al., 2009; Parkhurst et al., 2013). Other cell types in the brain, endothelial cells, astrocytes, and neurons, can also contribute to inflammatory responses in the brain. They also express innate immune receptors and can directly respond to DAMPs or PAMPs. In a resting state microglia cells have a ramified morphology, they have a large number of processes that enable the interaction of microglia with neurons and astrocytes. They search for dysfunctional synapses, which they are able to eliminate by phagocytosis (Wake et al., 2009; Tremblay et al., 2010). After immunological stimuli, like viral infection or brain injury microglia cells are activated (Davalos et al., 2005; Nimmerjahn et al., 2005) and acquire a compact phenotype. They upregulate several surface receptors, like receptors for neuro-transmitters, cytokines and chemokines, as well as PRRs (Rock et al., 2004; Block et al., 2007). Several TLRs are expressed on microglial surface, including TLR2, TLR4 and TLR6 (Udan et al., 2008; Stewart et al., 2010; Fellner et al., 2013). Activation of TLR4 together with CD14 is implicated in brain inflammation and microglial activation in response to sepsis (Chakravarty and Herkenham, 2005). The activation of microglia also leads to production of reactive oxygen species (ROS) through the induction or activation of NADPH (Shimohama et al., 2000) and NO (Vodovotz et al., 1996; Heneka et al., 2001).
Astrocytes provide neuronal support in healthy conditions and can undergo several phenotypic changes that could be protective or causative with regard to pathology (Sofroniew and Vinters, 2010). For the difference from microglia astrocytes descend from neuroepithelial stem cells. Upon triggering of TLR, astrocytes participate in innate immune reactions and secrete inflammatory mediators, like complement components, IL-1β and IL-6. It was reported that astrocyte exposure to LPS switches astrocyte of pro-inflammatory genes expression (Hamby et al., 2012; Zamanian et al., 2012). Interestingly, the ischemeia caused by experimental stroke in vivo shifts the astrocyte transcriptome towards neuroprotective mechanisms (Zamanian et al., 2012). Although astrocytes may undergo distinct phenotypic changes and secrete pro-inflammatory cytokines, recent study demonstrated that NLRP3 inflammasome was not functional in mouse astrocytes, but only in microglia cells (Gustin et al., 2015). However, it was reported that in human astrocytes NLRP2 inflammasome was activated by the ATP and the procersing of caspase 1 and IL-1β was confirmed (Minkiewicz et al., 2013). Activation of innate immune receptors, as well as inflammasome activationa and IL-1β release activate NF-κB signaling.
NF-κB
Nuclear factor kappa B (NF-κB) was first described by David Baltimore, as an inducible transcription factor in lymphocytes (Sen and Baltimore, 1986). In the CNS, NF-κB signaling is essential in several of physiological as well as pathological processes associated with neurodegeneration (Kaltschmidt et al., 1997; Ghosh et al., 2007; Crampton and O’Keeffe, 2013). The NF-κB family comprises several transcription factors that contain Rel-homology domains (RHDs) that bind to specific DNA sequences known as κB sites present in promoter and enhancer regions of various genes (Hayden and Ghosh, 2012). In mammalian cells five NF-κB factors were described: RelA (p65), RelB, c-Rel, p105 (NF-κB1; a precursor of p50) and p100 (NF-κB2; a precursor of p52; May and Ghosh, 1997). Homo- and heterodimers dimers could be formed through N-terminal DNA-binding/dimerization domain, known as the Rel homology domain. NF-κB dimers can modulate gene expression by binding to a variety of DNA sequences called κB sites (Karin, 2009). RelB, c-Rel, and p65 contain C-terminal transcription activation domains that enable recruitment of co-activator and target gene expression. p50 and p52 could form heterodimers with p65, c-Rel, or RelB and activate transcription of target genes. In addition, when they form homodimers, they repress transcription on binding to DNA (Hayden and Ghosh, 2011). In resting cells, NF-κB complexes are inactive, located mainly in the cytoplasm in a complex with IκB proteins. The IκB inhibitors contain ankyrin repeats and seven different inhibitors were described: IκBα, IκBβ, IκBε, IκBζ, p100, p105, Bcl3, IκBns. IκBα, IκBβ, IκBγ and IκBε can hide the nuclear localization signal of NF-κB in the cytoplasm by direct interactions and this way prevent nuclear translocation of NF-κB. On the other hand, Bcl-3, IκBζ and IκBNS are present in the nucleus and interact with NF-κB to regulate transcription (Hayden and Ghosh, 2008; Karin, 2009). Upon activation of innate receptors and signaling the rapid phosphorylation of specific serine residues of IκB proteins by a multiprotein complex termed the IKK complex occurs. IKK complex consists of two catalytically active kinases, IKKα and IKKβ, and a regulatory protein NEMO (NF-κB essential modifier, also known as IKKγ). IKKα and IKKβ are structurally similar and have a kinase domain, a leucine zipper domain, helix–loop–helix structures and a NEMO-binding domain (NBD). The IκB proteins are degraded by proteasome and NF-κB dimers enter the nucleus. IκBβ plays a unique role in determining specific target gene expression; it preferentially binds cRel-containing NF-κB dimers, and these dimer combinations bind to specific DNA sequences and selective downstream genes are targeted (Sen and Smale, 2010). Several different stimuli could trigger NF-κB signaling in the CNS, including cytokines (tumor necrosis factor κ (TNFα) and IL-(1), chemokines, virus as well as injury or oxidative stress. In some cases stimuli are specific for a cell type.NF-κB is activated by stimuli specific of the CNS like neural cell adhesion molecule (N-CAM; Krushel et al., 1999), neurotrophins (NGF and S100ββ; Carter et al., 1996) or amyloid β (Aβ) peptide (Behl et al., 1994). NF-κB enables the transcription of the genes encoding many pro-inflammatory cytokines and chemokines. Since cells from Nemo-deficient mice do not exhibit NF-κB activation by LPS or IL-1 (Rudolph et al., 2000), activation of NF-κB responsive genes by the innate immune triggers depends on NEMO and progresses through the canonical NF-κB signaling pathway. The expression of inducible NO synthase (iNOS), that mediates NO production, is regulated by NF-κB and STAT transcription factors (Farlik et al., 2010). The targets of NF-κB-dependent pro-inflammatory cytokines, such as TNFα, tend to be receptors that in turn, activate NF-κB pathway. NF-κB is critical to the propagation and elaboration of cytokine responses. TNF-α plays an important role in both local and systemic inflammation, and it is a powerful inducer of NF-κB. The predominant pathway triggered by TLR signaling is the canonical NF-κB pathway, where IKKβ-dependent phosphorylation of IκBα or IκBβ results in their ubiquitination and degradation by the proteasome (Kawai and Akira, 2007). The nuclear NF-κB dimers bind to κB DNA sites and start a transcriptional program that includes numerous effectors of the innate immune system. In the alternative (or non-canonical) pathway, both p105 and p100 contain C-terminal ankyrin repeats that function as IκB-like proteins. The p100-RelB complex is activated by phosphorylation of the C-terminal region of p100 by an IKKα–IKKα homodimer (lacking IKKβ and NEMO), which leads to ubiquitination and further degradation of the p100 IkB-like C-terminal sequences to generate a p52-RelB heterodimer (Sun, 2011). This pathway is triggered by CD40, LT (lymphotoxin) β receptor and the BAFF (B-cell-activating factor belonging to the TNF family) receptor.
In either pathway, the unmasked NF-kB complex can then enter the nucleus to activate target gene expression. In the classical pathway, one of the target genes activated by NF-κB is that which encodes IkBα. Newly-synthesized IkBα can enter the nucleus, remove NF-κB from DNA, and export the complex back to the cytoplasm to restore the original latent state. Furthermore, IKKα-deficient mice show increased production of pro-inflammatory chemokines and cytokine and show increased inflammatory responses in local and systemic inflammation (Lawrence et al., 2005; Li et al., 2005). The IKKα-mediated repression of transcriptional responses influence the level of nuclear p65 and c-Rel (Lawrence et al., 2005). Recent reports have shown that IKKβ also influence anti-inflammatory response in macrophages. IKKβ not only inhibits macrophage function by interfering with the STAT pathway during infection (Fong et al., 2008), but also suppresses the secretion of IL-1β (Greten et al., 2007). In the CNS, NF-κB activation can be negatively regulated by a several cytokines like IL-4, IL-10, transforming growth factor β (TGFβ), and other molecules like glycogen synthase kinase-3 (GSK-3β) and glucocorticoids (Kaltschmidt et al., 2005). During neuro inflammation in activated glial cells IL-4 inhibits NF-κB via a peroxisome proliferator activated receptor (PPAR)-γ-mediated mechanism and allows survival of differentiating oligodendrocyte precursors (Paintlia et al., 2006). Other studies demonstrated that GSK-3β negatively regulated NF-κB activity in astrocytes (Sanchez et al., 2003). Moreover, it was reported that IL-4 and IL-10 that block IL-1β-induced NF-κB activation in astrocytes, also diminished IL-1β-induced Akt phosphorylation (Pousset et al., 2000).
Cystatins
Cystatin is a name derived from cysteine protease inhibitor. They are reversible and tight-binding inhibitors of the papain (C1) and legumain (C13) families of cysteine proteases and have significant similarities in amino acid sequence (Barrett, 1981; Barrett et al., 1986). The MEROPS database (http://merops.sanger.ac.uk/) lists members of the cystatin family (family I25, clan IH), distributed in protozoa, plants, fungi and animals as well as in viruses (Rawlings et al., 2014). Initially, they were characterized as inhibitors of endolysosomal cysteine cathepsins, however recently some alternative functions for cystatins were proposed. Endolysosomal proteases and their inhibitors play an important role in the initiation and regulation of immune response (Bird et al., 2009; Kopitar-Jerala, 2012). On the basis of sequence homology, the presence or absence of disulfide bonds and physiological localization, of three families of cystatins were described: family I (stefins), family II (cystatins) and family III (kininogens; Kopitar-Jerala, 2006; Turk et al., 2008). Type 1 cystatins—stefins are mostly intracellular cystatins present in the cytosol, mitochondria and the nuclei (Abrahamson et al., 1986; Ceru et al., 2010; Maher et al., 2014a). Type 2 cystatins are mainly extracellular, secreted proteins. They are synthesized with 20–26 residue long signal peptides and most of them are found in physiologically relevant concentrations in body fluids (Abrahamson et al., 1986; Kopitar-Jerala, 2006; Turk et al., 2008). Type II cysatins possess also a second reactive site for inhibition of the C13 family of cysteine proteases (legumain; Alvarez-Fernandez et al., 1999). Cystatin C is expressed in a variety of tissues and its expression and localization was associated with various neurodegenerative pathologies like Alzheimer’s disease (AD; Kaur and Levy, 2012). It associates with Aβ and inhibits Aβ oligomerization in vitro and in vivo (Mi et al., 2007). A point mutation in the cystatin C gene is responsible for the dominantly inherited icelandic type of amyloidosis, hereditary cystatin C amyloid angiopathy (HCCAA; Olafsson and Grubb, 2000). The increased expression of cystatin C was observed in response to different types of insults to the brain, such as ischemia and epilepsy (Palm et al., 1995; Lukasiuk et al., 2002). Another type II cystatin, cystatin F was found abundant in the cells of the immune system: myeloid cells (macrophages and dendritic cells) and the cells involved in target cell killing (NK cells and cytotoxic T cells (CTLs; Halfon et al., 1998; Ni et al., 1998; Obata-Onai et al., 2002). It is expressed as di-sulfide-linked dimer (Cappello et al., 2004) and translocated to endolysosomes where it regulates cathepsin activity. Cystain F transport to endolysosomes depends on its N-linked glycosylation and it was reported that the secreted dimeric cystatin F could be internalized and activated by the mannose-6-phosphate receptor system (Colbert et al., 2009). Cleavage of its N-terminal region by cathepsin V leads to the monomerization and influence the inhibitory properties (Maher et al., 2014b). After proteolytic removal of its N-terminal part, cystatin F becomes a potent inhibitor of cathepsin C with the potential to regulate pro-granzyme processing and cell cytotoxicity (Hamilton et al., 2008). In cytotoxic cells, cystatin F therefore appears as a key regulator of granzyme processing and consequently cell cytotoxicity. Cystatin D was reported to inhibit proliferation, migration and invasion of carcinoma cells (Alvarez-Díaz et al., 2009). In addition, it was shown that a proportion of cystatin D is targeted to cell nucleus at specific transcriptionally active chromatin sites (Ferrer-Mayorga et al., 2015). Type-3 cystatins are high molecular weight (60–120 kDa) proteins and have three repeated type 2-like cystatin domains (Salvesen et al., 1986). Cystatins in immune cells have been reported to participate in the release of NO, phagocytosis and expression of cytokines (Kopitar-Jerala, 2006; Magister and Kos, 2013; Maher et al., 2014a). Stefin B belongs to the type one cystatins and is located in the cytosol, mitochondria and nucleus (Ceru et al., 2010; Maher et al., 2014a). Mutations in the gene encoding stefin B are present in patients with a form of progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1; Pennacchio et al., 1996, 1998; Lalioti et al., 1997a, b). EPM1 is an autosomal recessively inherited neurodegenerative disease, characterized by the cerebellar granule neurons apoptosis, progressive ataxia and myoclonic epilepsy (Pennacchio et al., 1996; Joensuu et al., 2008). In lymphoid cells of EPM1 patients, increased cathepsin activity, due to reduced expression of stefin B was reported (Rinne et al., 2002), we determined increased overall cathepsin activity in untreated, as well as in classically activated stefin B-deficient BMDMs compared to wild type cells (Maher et al., 2014c). We showed that in the nucleus stefin B interacts with cathepsin L and nucleosomes, specifically with histones H2A.Z, H2B, and H3 (Ceru et al., 2010). Goulet et al. (2004) has shown that only shorter procathepsin L isoforms translocate to the nucleus and stimulate processing of the CUX1 transcription factor at the G1/S transition of the cell cycle. The delay in cell cycle progression in cells overexpressing stefin B was associated with the inhibition of cathepsin L in the nucleus, confirmed by decreased cleavage of the CUX1 transcription factor (Ceru et al., 2010). In addition, we have shown that stefin B overexpression in the nucleus of astrocytoma cells T89G delayed not only cell cycle progression, but also caspase activation (Sun et al., 2012). A recent work demonstrated that the early microglial activation precedes neuronal loss in the brain of the stefin B deficient mice (Tegelberg et al., 2012). In our recent work we showed that stefin B-deficient mice were significantly more sensitive to the lethal LPS-induced sepsis due to increased caspase-11 expression (Maher et al., 2014a). The increased caspase-11 gene expression and better caspase-1 and -11 processing determined in stefin B deficient bone marrow-derived macrophages (BMDMs) resulted in enhanced IL-1β and IL-18 processing and secretion (Figure 1). Upon LPS stimulation, stefin B was targeted into the mitochondria, and the lack of stefin B resulted in the increased destabilization of mitochondrial membrane potential and mitochondrial ROS generation. We have determined increased NF-κB signaling in stefin B deficient BMDMS upon LPS stimulation, in reverse experiment when stefin B was over-expressed in macrophage reporter cell line RAW-blue, a decreased NF-κB activation was determined upon LPS stimulation (Maher et al., 2014a). The expression of caspase-11 is regulated by NF-κB and STAT-1 transcription factors (Schauvliege et al., 2002). Since STAT-1 signaling is downregulated in stefin B deficient BMDMs upon LPS stimulation. We propose that stefin B could modulate the caspase-11 gene expression in an NF-κB-dependent manner. Okuneva et al. (2015) reported significantly higher stefin B mRNA expression in microglia than in neurons or astrocytes, which is in line with our observation that stefin B is highly upregulated in activated macrophages (Maher et al., 2014c). In stefin B-deficient macrophages we detected increased LPS-induced pro-inflammatory NO production, but decreased IL-10 expression (Maher et al., 2014c). The phosphorylation of ERK and JNK MAP-kinases were significantly decreased in stefin B-deficient macrophages, as well as STAT-3 phosphorylation. The results in macrophages could be compared to the signaling events in microglia. Activation of cocultures of microglial and astroglial cells with LPS strongly induces IL-10 mRNA expression, IL-10 production and release (Ledeboer et al., 2002).
Figure 1
Innate receptor signaling and stefin B influence NF-κB activation and caspase-11 expression in macrophages. Stefin B could act an inhibitor of cysteine cathepsins in cytosol (1) and nucleus (2) in mitochondria (3) prevents the excessive ROS formation. Toll-like receptor (TLR) signaling is activated by TLR ligands. Signaling through TLR4 which is located in plasma membrane activate NF-κB via MyD88 dependent pathway. Moreover, caspase-11 expression is regulated by NF-κB signaling. In addition, LPS stimulation results in increased mitochondrial ROS formation. LPS stimulation could lead to non-canonical inflammasome activation of caspase-11 and caspase-1 that results in IL-1β and IL-18 processing and secretion.
Among type II cystatins, the most abundant cystatin is cystatin C. It was described first as a “post-γ-globulin” or “γ-trace” (Grubb and Löfberg, 1982). It is expressed in various tissues and mostly secreted from the cells (Abrahamson et al., 1986). In the CNS, cystatin C is secreted from the choroid plexus into the cerebrospinal fluid. Various studies showed that cystain C has a neuroprotective role in neurodegenerative diseases (Mi et al., 2007; Kaur and Levy, 2012). Frendéus et al. (2009) reported that mouse peritoneal macrophages lacking cystatin C expressed higher levels of IL-10 mRNA but lower TNF-α upon IFN-γ stimulation, compared to similarly primed wild type cells. The cystatin C-deficient macrophages also have reduced NF-κB p65 activation, compared to control cells. The precise mechanism by which cystatin C influence increased IL-10 expression is still elusive. Electrophoretic mobility shift analysis of nuclear extracts from macrophages and showed that IL-10 suppressed nuclear localization of NF-κB (Lentsch et al., 1997). Increased IL-10 expression could suppers NF-κB activation in cystatin C deficient cells.
Conclusions
The precise mechanism by which type I cystatins, like stefin B and type II cystatins cystatin C influence is still not clear. The type one cystatins, stefins A and B are localized to the cytoplasm and nucleus, while type II cystatins are predominately secreted. In addition, upon LPS stimulation stefin B is targeted to mitochondria and prevents excessive mitochondrial ROS formation. The lack of stefin B resulted in increased mitochondrial ROS formation and an increased NF-κB activation, as well as the expression of NF-κB target genes. Increased expression of stefin B in macrophages resulted in diminished NF-κB signaling, while exogenous addition of cystatin C to macrophages enhanced NF-κB p65 activity and NF-κB target genes expression. Further experiments on cell cultures as well as on mouse models could help us to elucidate the precise mechanism by which cystatins influence NF-κB signaling. Better understanding of the role of cystatins in these signaling pathways could lead also to the development of new therapies and medications.
Statements
Acknowledgments
This work was supported by the Slovenian Research Agency Grants : P-0140.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Abrahamson M. Barrett A. J. Salvesen G. Grubb A. (1986). Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J. Biol. Chem.261, 11282–11289.
2
Adamczak S. E. de Rivero Vaccari J. P. Dale G. Brand F. J. III Nonner D. Bullock M. R. et al . (2014). Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J. Cereb. Blood Flow Metab.34, 621–629. 10.1038/jcbfm.2013.236
3
Aguzzi A. Barres B. A. Bennett M. L. (2013). Microglia: scapegoat, saboteur, or something else?Science339, 156–161. 10.1126/science.1227901
4
Akira S. Uematsu S. Takeuchi O. (2006). Pathogen recognition and innate immunity. Cell124, 783–801. 10.1016/j.cell.2006.02.015
5
Alboni S. Cervia D. Sugama S. Conti B. (2010). Interleukin 18 in the CNS. J. Neuroinflammation7:9. 10.1186/1742-2094-7-9
6
Allan S. M. Tyrrell P. J. Rothwell N. J. (2005). Interleukin-1 and neuronal injury. Nat. Rev. Immunol.5, 629–640. 10.1038/nri1664
7
Alvarez-Díaz S. Valle N. García J. M. Peña C. Freije J. M. Quesada V. et al . (2009). Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J. Clin. Invest.119, 2343–2358. 10.1172/jci37205
8
Alvarez-Fernandez M. Barrett A. J. Gerhartz B. Dando P. M. Ni J. Abrahamson M. (1999). Inhibition of mammalian legumain by some cystatins is due to a novel second reactive site. J. Biol. Chem.272, 19195–19203.
9
Apostolou E. Thanos D. (2008). Virus infection induces NF-κB-dependent interchromosomal associations mediating monoallelic IFN-β gene expression. Cell134, 85–96. 10.1016/j.cell.2008.05.052
10
Banerjee S. Bhat M. A. (2007). Neuron-glial interactions in blood-brain barrier formation. Annu. Rev. Neurosci.30, 235–258. 10.1146/annurev.neuro.30.051606.094345
11
Barrett A. J. (1981). Alpha 2-macroglobulin. Methods Enzymol.80, 737–754. 10.1016/S0076-6879(81)80056-0
12
Barrett A. J. Fritz H. Grubb A. Isemura S. Jarvinen M. Katunuma N. et al . (1986). Nomenclature and classification of the proteins homologous with the cysteine-proteinase inhibitor chicken cystatin. Biochem. J.236:312. 10.1042/bj2360312
13
Bauernfeind F. G. Horvath G. Stutz A. Alnemri E. S. Macdonald K. Speert D. et al . (2009). Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol.183, 787–791. 10.4049/jimmunol.0901363
14
Behl C. Davis J. B. Lesley R. Schubert D. (1994). Hydrogen peroxide mediates amyloid β protein toxicity. Cell77, 817–827. 10.1016/0092-8674(94)90131-7
15
Bird P. I. Trapani J. A. Villadangos J. A. (2009). Endolysosomal proteases and their inhibitors in immunity. Nat. Rev. Immunol.9, 871–882. 10.1038/nri2671
16
Block M. L. Zecca L. Hong J. S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci.8, 57–69. 10.1038/nrn2038
17
Broz P. Monack D. M. (2013). Noncanonical inflammasomes: caspase-11 activation and effector mechanisms. PLoS Pathog.9:e1003144. 10.1371/journal.ppat.1003144
18
Cappello F. Gatti E. Camossetto V. David A. Lelouard H. Pierre P. (2004). Cystatin F is secreted, but artificial modification of its C-terminus can induce its endocytic targeting. Exp. Cell Res.297, 607–618. 10.1016/j.yexcr.2004.03.048
19
Carter B. D. Kaltschmidt C. Kaltschmidt B. Offenhäuser N. Böhm-Matthaei R. Baeuerle P. A. et al . (1996). Selective activation of NF-κB by nerve growth factor through the neurotrophin receptor p75. Science272, 542–545. 10.1126/science.272.5261.542
20
Ceru S. Konjar S. Maher K. Repnik U. Krizaj I. Bencina M. et al . (2010). Stefin B interacts with histones and cathepsin L in the nucleus. J. Biol. Chem.285, 10078–10086. 10.1074/jbc.m109.034793
21
Chakravarty S. Herkenham M. (2005). Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J. Neurosci.25, 1788–1796. 10.1523/jneurosci.4268-04.2005
22
Colbert J. D. Plechanovová A. Watts C. (2009). Glycosylation directs targeting and activation of cystatin F from intracellular and extracellular sources. Traffic10, 425–437. 10.1111/j.1600-0854.2009.00881.x
23
Crampton S. J. O’Keeffe G. W. (2013). NF-κB: emerging roles in hippocampal development and function. Int. J. Biochem. Cell Biol.45, 1821–1824. 10.1016/j.biocel.2013.05.037
24
Davalos D. Grutzendler J. Yang G. Kim J. V. Zuo Y. Jung S. et al . (2005). ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci.8, 752–758. 10.1038/nn1472
25
de Rivero Vaccari J. P. Lotocki G. Alonso O. F. Bramlett H. M. Dietrich W. D. Keane R. W. (2009). Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J. Cereb. Blood Flow Metab.29, 1251–1261. 10.1038/jcbfm.2009.46
26
Farlik M. Reutterer B. Schindler C. Greten F. Vogl C. Muller M. et al . (2010). Nonconventional initiation complex assembly by STAT and NF-κB transcription factors regulates nitric oxide synthase expression. Immunity33, 25–34. 10.1016/j.immuni.2010.07.001
27
Fellner L. Irschick R. Schanda K. Reindl M. Klimaschewski L. Poewe W. et al . (2013). Toll-like receptor 4 is required for [alpha]-synuclein dependent activation of microglia and astroglia. Glia61, 349–360. 10.1002/glia.22437
28
Ferrer-Mayorga G. Alvarez-Díaz S. Valle N. De Las Rivas J. Mendes M. Barderas R. et al . (2015). Cystatin D locates in the nucleus at sites of active transcription and modulates gene and protein expression. J. Biol. Chem.290, 26533–26548. 10.1074/jbc.m115.660175
29
Fong C. H. Bebien M. Didierlaurent A. Nebauer R. Hussell T. Broide D. et al . (2008). An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation. J. Exp. Med.205, 1269–1276. 10.1084/jem.20080124
30
Franchi L. Muñoz-Planillo R. Núñez G. (2012). Sensing and reacting to microbes through the inflammasomes. Nat. Immunol.13, 325–332. 10.1038/ni.2231
31
Freeman L. C. Ting J. P. (2015). The pathogenic role of the inflammasome in neurodegenerative diseases. J. Neurochem. [Epub ahead of print]. 10.1111/jnc.13217
32
Frendéus K. H. Wallin H. Janciauskiene S. Abrahamson M. (2009). Macrophage responses to interferon-gamma are dependent on cystatin C levels. Int. J. Biochem. Cell Biol.41, 2262–2269. 10.1016/j.biocel.2009.05.005
33
Ghosh A. Roy A. Liu X. Kordower J. H. Mufson E. J. Hartley D. M. et al . (2007). Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc. Natl. Acad. Sci. U S A104, 18754–18759. 10.1073/pnas.0704908104
34
Goulet B. Baruch A. Moon N. S. Poirier M. Sansregret L. L. Erickson A. et al . (2004). A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell14, 207–219. 10.1016/s1097-2765(04)00209-6
35
Greten F. R. Arkan M. C. Bollrath J. Hsu L. C. Goode J. Miething C. et al . (2007). NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell130, 918–931. 10.1016/j.cell.2007.07.009
36
Grubb A. Löfberg H. (1982). Human gamma-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc. Natl. Acad. Sci. U S A79, 3024–3027. 10.1073/pnas.79.9.3024
37
Guo H. Callaway J. B. Ting J. P. Y. (2015). Inflammasomes: mechanism of action, role in disease and therapeutics. Nat. Med.21, 677–687. 10.1038/nm.3893
38
Gustin A. Kirchmeyer M. Koncina E. Felten P. Losciuto S. Heurtaux T. et al . (2015). NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes. PLoS One10:e0130624. 10.1371/journal.pone.0130624
39
Hagar J. A. Powell D. A. Aachoui Y. Ernst R. K. Miao E. A. (2013). Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science341, 1250–1253. 10.1126/science.1240988
40
Halfon S. Ford J. Foster J. Dowling L. Lucian L. Sterling M. et al . (1998). Leukocystatin, a new class II cystatin expressed selectively by hematopoietic cells. J. Biol. Chem.273, 16400–16408. 10.1074/jbc.273.26.16400
41
Halle A. Hornung V. Petzold G. C. Stewart C. R. Monks B. G. Reinheckel T. et al . (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol.9, 857–865. 10.1038/ni.1636
42
Hamby M. E. Coppola G. Ao Y. Geschwind D. H. Khakh B. S. Sofroniew M. V. (2012). Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors. J. Neurosci.32, 14489–14510. 10.1523/JNEUROSCI.1256-12.2012
43
Hamilton G. Colbert J. D. Schuettelkopf A. W. Watts C. (2008). Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis. EMBO J.27, 499–508. 10.1038/sj.emboj.7601979
44
Hayden M. S. Ghosh S. (2008). Shared principles in NF-κB signaling. Cell132, 344–362. 10.1016/j.cell.2008.01.020
45
Hayden M. S. Ghosh S. (2011). NF-κB in immunobiology. Cell Res.21, 223–244. 10.1038/cr.2011.13
46
Hayden M. S. M. Ghosh S. S. (2012). NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev.26, 203–234. 10.1101/gad.183434.111
47
Heneka M. T. Golenbock D. T. Latz E. (2015). Innate immunity in Alzheimer’s disease. Nat. Immunol.16, 229–236. 10.1038/ni.3102
48
Heneka M. T. Kummer M. P. Latz E. (2014). Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol.14, 463–477. 10.1038/nri3705
49
Heneka M. T. Wiesinger H. Dumitrescu-Ozimek L. Riederer P. Feinstein D. L. Klockgether T. (2001). Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J. Neuropathol. Exp. Neurol.60, 906–916. 10.0022-3069/jbr.2985192r
50
Jabaut J. Ather J. L. Taracanova A. Poynter M. E. Ckless K. (2013). Mitochondria-targeted drugs enhance Nlrp3 inflammasome-dependent IL-1β secretion in association with alterations in cellular redox and energy status. Free Radic. Biol. Med.29, 233–245. 10.1016/j.freeradbiomed.2013.01.025
51
Joensuu T. Lehesjoki A. E. Kopra O. (2008). Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia49, 557–563. 10.1111/j.1528-1167.2007.01422.x
52
Kajiwara Y. Schiff T. Voloudakis G. Gama Sosa M. A. Elder G. Bozdagi O. et al . (2014). A critical role for human caspase-4 in endotoxin sensitivity. J. Immunol.193, 335–343. 10.4049/jimmunol.1303424
53
Kaltschmidt B. Uherek M. Volk B. Baeuerle P. A. Kaltschmidt C. (1997). Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U S A94, 2642–2647. 10.1073/pnas.94.6.2642
54
Kaltschmidt B. Widera D. Kaltschmidt C. (2005). Signaling via NF-κB in the nervous system. Biochim. Biophys. Acta1745, 287–299. 10.1016/j.bbamcr.2005.05.009
55
Karin M. (2009). NF-κB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol.1:a000141. 10.1101/cshperspect.a000141
56
Kaur G. Levy E. (2012). Cystatin C in Alzheimer’s disease. Front. Mol. Neurosci.5:79. 10.3389/fnmol.2012.00079
57
Kawai T. Akira S. (2007). Signaling to NF-κB by Toll-like receptors. Trends Mol. Med.13, 460–469. 10.1016/j.molmed.2007.09.002
58
Kawai T. Akira S. (2009). The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol.21, 317–337. 10.1093/intimm/dxp017
59
Kayagaki N. Stowe I. B. Lee B. L. O’Rourke K. Anderson K. Warming S. et al . (2015). Caspase-11 cleaves gasdermin D for non-canonical inflammasome signaling. Nature526, 666–671. 10.1038/nature15541
60
Kayagaki N. Warming S. Lamkanfi M. Vande Walle L. Louie S. Dong J. et al . (2011). Non-canonical inflammasome activation targets caspase-11. Nature479, 117–121. 10.1038/nature10558
61
Kayagaki N. Wong M. T. Stowe I. B. Ramani S. R. Gonzalez L. C. Akashi-Takamura S. et al . (2013). Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science341, 1246–1249. 10.1126/science.1240248
62
Kobayashi K. Hernandez L. D. Galán J. E. Janeway C. A. Jr. Medzhitov R. Flavell R. A. (2002). IRAK-M is a negative regulator of Toll-like receptor signaling. Cell110, 191–202. 10.1016/s0092-8674(02)00827-9
63
Kopitar-Jerala N. (2006). The role of cystatins in cells of the immune system. FEBS Lett.580, 6295–6301. 10.1016/j.febslet.2006.10.055
64
Kopitar-Jerala N. (2012). The role of cysteine proteinases and their inhibitors in the host-pathogen cross talk. Curr. Protein Pept. Sci.13, 767–775. 10.2174/138920312804871102
65
Krushel L. A. Cunningham B. A. Edelman G. M. Crossin K. L. (1999). NF-κB activity is induced by neural cell adhesion molecule binding to neurons and astrocytes. J. Biol. Chem.274, 2432–2439. 10.1074/jbc.274.4.2432
66
Lalioti M. D. Mirotsou M. Buresi C. Peitsch M. C. Rossier C. Ouazzani R. et al . (1997a). Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am. J. Hum. Genet.60, 342–351.
67
Lalioti M. D. Scott H. S. Buresi C. Rossier C. Bottani A. Morris M. A. et al . (1997b). Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature386, 847–851. 10.1038/386847a0
68
Lamkanfi M. Dixit V. M. (2014). Mechanisms and functions of inflammasomes. Cell157, 1013–1022. 10.1016/j.cell.2014.04.007
69
Latz E. Xiao T. S. Stutz A. (2013). Activation and regulation of the inflammasomes. Nat. Rev. Immunol.13, 397–411. 10.1038/nri3452
70
Lawrence T. Bebien M. Liu G. Y. Nizet V. Karin M. (2005). IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature434, 1138–1143. 10.1038/nature03491
71
Ledeboer A. Brevé J. J. P. Wierinckx A. van der Jagt S. Bristow A. F. Leysen J. E. et al . (2002). Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. Eur. J. Neurosci.16, 1175–1185. 10.1046/j.1460-9568.2002.02200.x
72
Lentsch A. B. Shanley T. P. Sarma V. Ward P. A. (1997). In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J. Clin. Invest.100, 2443–2448. 10.1172/jci119786
73
Li Q. Lu Q. Bottero V. Estepa G. Morrison L. Mercurio F. et al . (2005). Enhanced NF-κB activation and cellular function in macrophages lacking IκB kinase 1 (IKK1). Proc. Natl. Acad. Sci. U S A102, 12425–12430. 10.1073/pnas.0505997102
74
Lukasiuk K. Pirttilä T. J. Pitkänen A. (2002). Upregulation of cystatin C expression in the rat hippocampus during epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Epilepsia5, 137–145. 10.1046/j.1528-1157.43.s.5.20.x
75
Magister S. Kos J. (2013). Cystatins in immune system. J. Cancer4, 45–56. 10.7150/jca.5044
76
Maher K. Jerič Kokelj B. Butinar M. Mikhaylov G. Mancek-Keber M. Stoka V. et al . (2014a). A role for stefin B (cystatin B) in inflammation and endotoxemia. J. Biol. Chem.289, 31736–31750. 10.1074/jbc.M114.609396
77
Maher K. Konjar S. Watts C. Turk B. Kopitar-Jerala N. (2014b). Cystatin F regulates proteinase activity in IL-2-activated natural killer cells. Protein Pept. Lett.21, 957–965. 10.2174/0929866521666140403124146
78
Maher K. Završnik J. Jerič-Kokelj B. Vasiljeva O. Turk B. Kopitar-Jerala N. (2014c). Decreased IL-10 expression in stefin B-deficient macrophages is regulated by the MAP kinase and STAT-3 signaling pathways. FEBS Lett.588, 720–726. 10.1016/j.febslet.2014.01.015
79
Martinon F. Tschopp J. (2007). Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ.14, 10–22. 10.1038/sj.cdd.4402038
80
May M. J. Ghosh S. (1997). Rel/NF-κB and IκB proteins: an overview. Semin. Cancer Biol.8, 63–73. 10.1006/scbi.1997.0057
81
Medzhitov R. (2007). Recognition of microorganisms and activation of the immune response. Nature449, 819–826. 10.1038/nature06246
82
Mi W. Pawlik M. Sastre M. Jung S. S. Radvinsky D. S. Klein A. M. et al . (2007). Cystatin C inhibits amyloid-β deposition in Alzheimer’s disease mouse models. Nat. Genet.39, 1440–1442. 10.1038/ng.2007.29
83
Minkiewicz J. de Rivero Vaccari J. P. Keane R. W. (2013). Human astrocytes express a novel NLRP2 inflammasome. Glia61, 1113–1121. 10.1002/glia.22499
84
Moresco E. M. LaVine D. Beutler B. (2011). Toll-like receptors. Curr. Biol.21, R488–R493. 10.1016/j.cub.2011.05.039
85
Muzio M. Ni J. Feng P. Dixit V. M. (1997). IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science278, 1612–1615. 10.1126/science.278.5343.1612
86
Ni J. Fernandez A. Danielsson L. Chillakuru R. A. Zhang J. Grub A. et al . (1998). Cystatin F is a glycosylated human low molecular weight cystein proteinase inhibitor. J. Biol. Chem.273, 24797–24804. 10.1074/jbc.273.38.24797
87
Nimmerjahn A. Kirchhoff F. Helmchen F. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science308, 1314–1318. 10.1126/science.1110647
88
Obata-Onai A. Hashimoto S. Onai N. Kurachi M. Nagai S. Shizuno K. et al . (2002). Comprehensive gene expression analysis of human NK cells and CD8(+) T lymphocytes. Int. Immunol.14, 1085–1098. 10.1093/intimm/dxf086
89
Okuneva O. Körber I. Li Z. Tian L. Joensuu T. Kopra O. et al . (2015). Abnormal microglial activation in the Cstb−/− mouse, a model for progressive myoclonus epilepsy, EPM1. Glia63, 400–411. 10.1002/glia.22760
90
Olafsson I. Grubb A. (2000). Hereditary cystatin C amyloid angiopathy. Amyloid7, 70–79. 10.3109/13506120009146827
91
Paintlia A. S. Paintlia M. K. Singh I. Singh A. K. (2006). IL-4-induced peroxisome proliferator-activated receptor γ activation inhibits NF-κB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions: implication for CNS-demyelinating diseases. J. Immunol.176, 4385–4398. 10.4049/jimmunol.176.7.4385
92
Palm D. E. Knuckey N. W. Primiano M. J. Spangenberger A. G. Johanson C. E. (1995). Cystatin C, a protease inhibitor, in degenerating rat hippocampal neurons following transient forebrain ischemia. Brain Res.691, 1–8. 10.1016/0006-8993(95)00520-z
93
Parkhurst C. N. Yang G. Ninan I. Savas J. N. Yates J. R. 3rd Lafaille J. J. et al . (2013). Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell155, 1596–1609. 10.1016/j.cell.2013.11.030
94
Pennacchio L. A. Bouley D. M. Higgins K. M. Scott M. P. Noebels J. L. Myers R. M. (1998). Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat. Genet.20, 251–258. 10.1038/3059
95
Pennacchio L. A. Lehesjoki A. E. Stone N. E. Willour V. L. Virtaneva K. Miao J. et al . (1996). Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1) [see comments]. Science271, 1731–1734. 10.1126/science.271.5256.1731
96
Pousset F. Dantzer R. Kelly K. W. Parnet P. (2000). Interleukin-1 signaling in mouse astrocytes involves Akt: a study with interleukin-4 and interleukin-10. Eur. Cytokine Netw.11, 427–434.
97
Rathinam V. A. Vanaja S. K. Waggoner L. Sokolovska A. Becker C. Stuart L. M. et al . (2012). TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell150, 606–619. 10.1016/j.cell.2012.07.007
98
Rawlings N. D. Waller M. Barrett A. J. Bateman A. (2014). MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res.40, D343–D350. 10.1002/0471250953.bi0125s48
99
Rinne R. Saukko P. Järvinen M. Lehesjoki A. E. (2002). Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy. Ann. Med.34, 380–385. 10.1080/078538902320772124
100
Rock R. B. Gekker G. Hu S. Sheng W. S. Cheeran M. Lokensgard J. R. et al . (2004). Role of microglia in central nervous system infections. Clin. Microbiol. Rev.17, 942–964. 10.1128/cmr.17.4.942-964.2004
101
Rudolph D. Yeh W. C. Wakeham A. Rudolph B. Nallainathan D. Potter J. et al . (2000). Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice. Genes Dev.14, 854–862. 10.1101/gad.14.7.854
102
Salvesen G. Parkes C. Abrahamson M. Grubb A. Barrett A. J. (1986). Human low-Mr kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem. J.234, 429–434. 10.1042/bj2340429
103
Sanchez J. F. Sniderhan L. F. Williamson A. L. Fan S. Chakraborty-Sett S. Maggirwar S. B. (2003). Glycogen synthase kinase 3β-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor κB signaling. Mol. Cell. Biol.23, 4649–4662. 10.1128/mcb.23.13.4649-4662.2003
104
Schauvliege R. Vanrobaeys J. Schotte P. Beyaert R. (2002). Caspase-11 gene expression in response to lipopolysaccharide and interferon-gamma requires nuclear factor-κ B and signal transducer and activator of transcription (STAT) 1. J. Biol. Chem.277, 41624–41630. 10.1074/jbc.m207852200
105
Sen R. Baltimore D. (1986). Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell46, 705–716. 10.1016/0092-8674(86)90346-6
106
Sen R. Smale S. T. (2010). Selectivity of the NF-κB response. Cold Spring Harb. Perspect. Biol.2:a000257. 10.1101/cshperspect.a000257
107
Shi J. Zhao Y. Wang K. Shi X. Wang Y. Huang H. et al . (2015). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature526, 660–665. 10.1038/nature15514
108
Shimohama S. Tanino H. Kawakami N. Okamura N. Kodama H. Yamaguchi T. et al . (2000). Activation of NADPH oxidase in Alzheimer’s disease brains. Biochem. Biophys. Res. Commun.273, 5–9. 10.1006/bbrc.2000.2897
109
Sofroniew M. V. Vinters H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathol.119, 7–35. 10.1007/s00401-009-0619-8
110
Stewart C. R. Stuart L. M. Wilkinson K. van Gils J. M. Deng J. Halle A. et al . (2010). CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol.11, 155–161. 10.1038/ni.1836
111
Sun S. C. (2011). Non-canonical NF-κB signaling pathway. Cell Res.21, 71–85. 10.1038/cr.2010.177
112
Sun T. Turk V. Turk B. Kopitar-Jerala N. (2012). Increased expression of stefin B in the nucleus of T98G astrocytoma cells delays caspase activation. Front. Mol. Neurosci.5:93. 10.3389/fnmol.2012.00093
113
Takeuchi O. Akira S. (2010). Pattern recognition receptors and inflammation. Cell140, 805–820. 10.1016/j.cell.2010.01.022
114
Tegelberg S. Kopra O. Joensuu T. Cooper J. D. Lehesjoki A.-E. (2012). Early microglial activation precedes neuronal loss in the brain of the Cstb−/− mouse model of progressive myoclonus epilepsy, EPM1. J. Neuropathol. Exp. Neurol.71, 40–53. 10.1097/NEN.0b013e31823e68e1
115
Tremblay M. E. Lowery R. L. Majewska A. K. (2010). Microglial interactions with synapses are modulated by visual experience. PLoS Biol.8:e1000527. 10.1371/journal.pbio.1000527
116
Turk V. Stoka V. Turk D. (2008). Cystatins: biochemical and structural properties and medical relevance. Front. Biosci.13, 5406–5420. 10.2741/3089
117
Udan M. L. D. Ajit D. Crouse N. R. Nichols M. R. (2008). Toll-like receptors 2 and 4 mediate Abeta(1–42) activation of the innate immune response in a human monocytic cell line. J. Neurochem.104, 524–533. 10.1111/j.1471-4159.2007.05001.x
118
Visintin A. Latz E. Monks B. G. Espevik T. Golenbock D. T. (2003). Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J. Biol. Chem.278, 48313–48320. 10.1074/jbc.m306802200
119
Vodovotz Y. Lucia M. S. Flanders K. C. Chesler L. Xie Q. W. Smith T. W. et al . (1996). Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer’s disease. J. Exp. Med.184, 1425–1433. 10.1084/jem.184.4.1425
120
Wake H. Moorhouse A. J. Jinno S. Kohsaka S. Nabekura J. (2009). Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J. Neurosci.29, 3974–3980. 10.1523/JNEUROSCI.4363-08.2009
121
Wang S. Miura M. Jung Y. Zhu H. Gagliardini V. Shi L. et al . (1996). Identification and characterization of Ich-3, a member of the interleukin-1β converting enzyme (ICE)/Ced-3 family and an upstream regulator of ICE. J. Biol. Chem.271, 20580–20587. 10.1074/jbc.271.34.20580
122
Wang S. Miura M. Jung Y. K. Zhu H. Li E. Yuan J. (1998). Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell92, 501–509. 10.1016/s0092-8674(00)80943-5
123
Wesche H. Henzel W. J. Shillinglaw W. Li S. Cao Z. (1997). MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity7, 837–847. 10.1016/s1074-7613(00)80402-1
124
Zamanian J. L. Xu L. Foo L. C. Nouri N. Zhou L. Giffard R. G. et al . (2012). Genomic analysis of reactive astrogliosis. J. Neurosci.32, 6391–6410. 10.1523/JNEUROSCI.6221-11.2012
125
Zocchia C. Spiga G. Rabin S. J. Grekova M. Richert J. Chernyshev O. et al . (1997). Biological activity of interleukin-10 in the central nervous system. Neurochem. Int.30, 433–439. 10.1016/s0197-0186(96)00079-4
Summary
Keywords
astrocytes, cystatins, microglia, TLR, NF-kappa B, NLR inflammasome
Citation
Kopitar-Jerala N (2015) Innate Immune Response in Brain, NF-Kappa B Signaling and Cystatins. Front. Mol. Neurosci. 8:73. doi: 10.3389/fnmol.2015.00073
Received
31 August 2015
Accepted
16 November 2015
Published
09 December 2015
Volume
8 - 2015
Edited by
Jun Yan, The University of Queensland, Australia
Reviewed by
Asya Rolls, Technion–Israel Institute of Technology, Israel; Juan Pablo De Rivero Vaccari, University of Miami, USA
Updates
Copyright
© 2015 Kopitar-Jerala.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nataša Kopitar-Jerala natasa.kopitar@ijs.si
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.